BR9608033A - Inibidores de aspartil protease de heterociclo oxigenado contendo sulfonamida - Google Patents

Inibidores de aspartil protease de heterociclo oxigenado contendo sulfonamida

Info

Publication number: BR9608033A
Authority: BR; Brazil
Prior art keywords: sulphonamide; protease inhibitors; aspartyl protease; containing oxygenated; oxygenated heterocycle
Prior art date: 1995-04-19

Application number

BR9608033A

Other languages

English (en)

Inventor

Roger D Tung

Govinda Rao Bhisetti

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-19

Filing date

1996-04-18

Publication date

1999-01-12

1996-04-18 Application filed by Vertex Pharma filed Critical Vertex Pharma

1999-01-12 Publication of BR9608033A publication Critical patent/BR9608033A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
- C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Furan Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)

BR9608033A 1995-04-19 1996-04-18 Inibidores de aspartil protease de heterociclo oxigenado contendo sulfonamida BR9608033A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/424,810 US5691372A (en)	1995-04-19	1995-04-19	Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
PCT/US1996/005473 WO1996033187A1 (en)	1995-04-19	1996-04-18	Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease

Publications (1)

Publication Number	Publication Date
BR9608033A true BR9608033A (pt)	1999-01-12

Family

ID=23683966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9608033A BR9608033A (pt)	1995-04-19	1996-04-18	Inibidores de aspartil protease de heterociclo oxigenado contendo sulfonamida

Country Status (34)

Country	Link
US (2)	US5691372A (pt)
EP (3)	EP1637528B1 (pt)
JP (1)	JP4240532B2 (pt)
KR (1)	KR100485237B1 (pt)
CN (1)	CN1110491C (pt)
AP (2)	AP9600827A0 (pt)
AR (1)	AR004663A1 (pt)
AT (3)	ATE314360T1 (pt)
AU (1)	AU712913B2 (pt)
BG (1)	BG102041A (pt)
BR (1)	BR9608033A (pt)
CA (1)	CA2217745C (pt)
CO (1)	CO4700433A1 (pt)
CZ (1)	CZ329497A3 (pt)
DE (3)	DE69635679T2 (pt)
DK (1)	DK0833826T3 (pt)
EA (1)	EA000906B1 (pt)
EE (1)	EE9700254A (pt)
ES (3)	ES2256117T3 (pt)
GE (1)	GEP20001915B (pt)
HU (1)	HUP9801948A3 (pt)
IL (1)	IL117962A0 (pt)
IS (1)	IS4575A (pt)
MY (1)	MY115797A (pt)
NO (1)	NO974744D0 (pt)
NZ (1)	NZ307342A (pt)
PE (1)	PE43697A1 (pt)
PL (1)	PL322904A1 (pt)
PT (1)	PT833826E (pt)
SK (1)	SK143097A3 (pt)
TR (1)	TR199701194T1 (pt)
TW (1)	TW404945B (pt)
WO (1)	WO1996033187A1 (pt)
ZA (1)	ZA962891B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040122000A1 (en)	1981-01-07	2004-06-24	Vertex Pharmaceuticals Incorporated.	Inhibitors of aspartyl protease
ES2177868T3 (es)	1992-08-25	2002-12-16	Searle & Co	Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
US7141609B2 (en)	1992-08-25	2006-11-28	G.D. Searle & Co.	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5942253A (en)	1995-10-12	1999-08-24	Immunex Corporation	Prolonged release of GM-CSF
US6121273A (en) *	1996-12-31	2000-09-19	Gpi Nil Holdings, Inc	N-linked sulfonamides of heterocyclic thioesters
US5874449A (en) *	1996-12-31	1999-02-23	Gpi Nil Holdings, Inc.	N-linked sulfonamides of heterocyclic thioesters
BR9809124A (pt) *	1997-05-17	2000-08-01	Glaxo Group Ltd	Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
US5945441A (en)	1997-06-04	1999-08-31	Gpi Nil Holdings, Inc.	Pyrrolidine carboxylate hair revitalizing agents
US20010049381A1 (en)	1997-06-04	2001-12-06	Gpl Nil Holdings, Inc.,	Pyrrolidine derivative hair growth compositions and uses
US6576231B2 (en) *	1997-09-12	2003-06-10	Schering Ag	Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
BR9814484A (pt) *	1997-12-24	2000-10-10	Vertex Pharma	"pró-drogas de inibidores de aspartil protease"
US6436989B1 (en)	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
ES2235492T3 (es) *	1998-06-19	2005-07-01	Vertex Pharmaceuticals Incorporated	Inhibidores de aspartil proteasa de tipo sulfonamida.
CA2336160C (en)	1998-06-23	2015-02-17	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Use of compounds for treating hiv
US6395758B1 (en)	1998-08-14	2002-05-28	Gpi Nil Holdings, Inc.	Small molecule carbamates or ureas for vision and memory disorders
US6376517B1 (en)	1998-08-14	2002-04-23	Gpi Nil Holdings, Inc.	Pipecolic acid derivatives for vision and memory disorders
US6339101B1 (en)	1998-08-14	2002-01-15	Gpi Nil Holdings, Inc.	N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6399648B1 (en)	1998-08-14	2002-06-04	Gpi Nil Holdings, Inc.	N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6337340B1 (en)	1998-08-14	2002-01-08	Gpi Nil Holdings, Inc.	Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6218423B1 (en)	1998-08-14	2001-04-17	Gpi Nil Holdings, Inc.	Pyrrolidine derivatives for vision and memory disorders
US7338976B1 (en)	1998-08-14	2008-03-04	Gpi Nil Holdings, Inc.	Heterocyclic esters or amides for vision and memory disorders
US6462072B1 (en)	1998-09-21	2002-10-08	Gpi Nil Holdings, Inc.	Cyclic ester or amide derivatives
US6319946B1 (en)	1999-02-12	2001-11-20	Vertex Pharmaceuticals Incorporated	Inhibitors of aspartyl protease
EP1159278B1 (en) *	1999-02-12	2005-11-30	Vertex Pharmaceuticals Incorporated	Inhibitors of aspartyl protease
AR031520A1 (es) *	1999-06-11	2003-09-24	Vertex Pharma	Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
ATE398623T1 (de) *	1999-10-06	2008-07-15	Tibotec Pharm Ltd	Hexahydrofuro-2,3-b furan-3-yl-n- 3-,(1,3- benzodioxol-5-ylsulfonyl)(isobutyl)amino -1- benzyl-2-hydroxypropyl carbamat als retrovirusproteasehemmer
HUP0302631A2 (hu)	2000-03-30	2003-11-28	Bristol-Myers Squibb Co.	Stavudint tartalmazó elnyújtott hatóanyag-kibocsátású szemcsék
CN100491360C (zh) *	2001-04-09	2009-05-27	泰博特克药品有限公司	广谱2-(取代的-氨基)-苯并唑磺酰胺hiv蛋白酶抑制剂
AU2003202914A1 (en) *	2002-01-07	2003-07-24	Sequoia Pharmaceuticals	Broad spectrum inhibitors
US7157489B2 (en) *	2002-03-12	2007-01-02	The Board Of Trustees Of The University Of Illinois	HIV protease inhibitors
AU2003300375A1 (en) *	2002-10-11	2004-05-04	Semplastics, L.L.C.	Retaining ring for use on a carrier of a polishing apparatus
CA2507484A1 (en) *	2002-11-27	2004-06-17	Elan Pharmaceuticals, Inc.	Substituted ureas and carbamates
US20050131042A1 (en) *	2003-12-11	2005-06-16	Flentge Charles A.	HIV protease inhibiting compounds
US7763609B2 (en) *	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US20080194554A1 (en) *	2005-03-11	2008-08-14	Mclean Ed W	Hiv Protease Inhibitors
JP2007202679A (ja) *	2006-01-31	2007-08-16	Juki Corp	ミシンの糸調子装置
JP2007202833A (ja) *	2006-02-02	2007-08-16	Juki Corp	ミシンの糸調子装置
WO2008133734A2 (en) *	2006-11-21	2008-11-06	Purdue Research Foundation	Method and compositions for treating hiv infections
WO2009091941A1 (en)	2008-01-17	2009-07-23	Purdue Research Foundation	Small molecule inhibitors of hiv proteases
US8791135B2 (en)	2008-07-01	2014-07-29	Purdue Research Foundation	Nonpeptide HIV-1 protease inhibitors
WO2010006050A1 (en)	2008-07-09	2010-01-14	Purdue Research Foundation	Hiv protease inhibitors and methods for using
CN105272991B (zh) *	2014-06-26	2017-11-07	成都中医药大学	一种化合物晶型
US11090030B2 (en)	2016-11-10	2021-08-17	Leltek Inc.	Ultrasound apparatus and ultrasound emission method

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3743722A (en) *	1971-07-14	1973-07-03	Abbott Lab	Anti-coagulant isolation
FR2459235A1 (fr) *	1979-06-14	1981-01-09	Sanofi Sa	Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) *	1982-09-09	1984-03-15	Dainippon Ink & Chem Inc	含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) *	1982-09-13	1984-03-19	Dainippon Ink & Chem Inc	直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) *	1984-09-17	1986-04-12	Dainippon Ink & Chem Inc	界面活性剤組成物
US4616088A (en) *	1984-10-29	1986-10-07	E. R. Squibb & Sons, Inc.	Amino acid ester and amide renin inhibitor
US4629724A (en) *	1984-12-03	1986-12-16	E. R. Squibb & Sons, Inc.	Amino acid ester and amide renin inhibitors
DE3635907A1 (de) *	1986-10-22	1988-04-28	Merck Patent Gmbh	Hydroxy-aminosaeurederivate
GB2200115B (en) *	1987-01-21	1990-11-14	Sandoz Ltd	Novel peptide derivatives, their production and use
CA1340588C (en) *	1988-06-13	1999-06-08	Balraj Krishan Handa	Amino acid derivatives
IL91780A (en) *	1988-10-04	1995-08-31	Abbott Lab	History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007329A1 (en) *	1989-01-06	1990-07-12	The Regents Of The University Of California	Selection method for pharmacologically active compounds
US5354866A (en) *	1989-05-23	1994-10-11	Abbott Laboratories	Retroviral protease inhibiting compounds
US5151438A (en) *	1989-05-23	1992-09-29	Abbott Laboratories	Retroviral protease inhibiting compounds
IE902295A1 (en) *	1989-07-07	1991-01-16	Abbott Lab	Amino acid analog cck antagonists
GB8927913D0 (en) *	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
EP0532693A1 (en) *	1990-06-01	1993-03-24	The Du Pont Merck Pharmaceutical Company	1,4-diamino-2,3-dihydroxybutanes
TW225540B (pt) *	1990-06-28	1994-06-21	Shionogi & Co
AU9125191A (en) *	1990-11-19	1992-06-11	Monsanto Company	Retroviral protease inhibitors
DK0558657T3 (da) *	1990-11-19	1997-07-07	Monsanto Co	Retrovirale proteaseinhibitorer
ES2243959T3 (es) *	1990-11-19	2005-12-01	Monsanto Company	Inhibidores de proteasas retrovirales.
ATE155779T1 (de) *	1990-11-19	1997-08-15	Monsanto Co	Retrovirale protease-inhibitoren
IE913840A1 (en) *	1990-11-20	1992-05-20	Abbott Lab	Retroviral protease inhibiting compounds
ES2112880T3 (es) *	1991-11-08	1998-04-16	Merck & Co Inc	Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
CA2131182C (en) *	1992-05-20	2005-04-26	John S. Ng	Method for making intermediates useful in synthesis of retroviral protease inhibitors
EP0957093A3 (en) *	1992-05-21	2000-04-12	Monsanto Company	Retrovial protease inhibitors
ES2177868T3 (es) *	1992-08-25	2002-12-16	Searle & Co	Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
DK0656888T3 (da) *	1992-08-25	1998-02-09	Searle & Co	Sulfonylalkanoylaminohydroxyethylaminosulfonamider, anvendelige som retrovirale protease-inhibitorer
ATE154800T1 (de) *	1992-08-25	1997-07-15	Searle & Co	N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren
US5723490A (en) *	1992-09-08	1998-03-03	Vertex Pharmaceuticals Incorporated	THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is)	1992-09-08	2008-02-15	Vertex Pharmaceuticals Inc., (A Massachusetts Corporation)	Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ATE211462T1 (de) *	1992-10-30	2002-01-15	Searle & Co	N-substituierte hydroxyethylaminosulfamidsäure- derivate verwendbar als inhibitoren retroviraler proteasen
WO1994010136A1 (en) *	1992-10-30	1994-05-11	G.D. Searle & Co.	Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
WO1994018192A1 (en) *	1993-02-12	1994-08-18	Merck & Co., Inc.	Piperazine derivatives as hiv protease inhibitors
TW281669B (pt) *	1993-02-17	1996-07-21	Chugai Pharmaceutical Co Ltd
EP0715618B1 (en) *	1993-08-24	1998-12-16	G.D. Searle & Co.	Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
UA49803C2 (uk) *	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій

1995
- 1995-04-19 US US08/424,810 patent/US5691372A/en not_active Expired - Lifetime
1996
- 1996-04-11 ZA ZA962891A patent/ZA962891B/xx unknown
- 1996-04-11 TW TW085104278A patent/TW404945B/zh not_active IP Right Cessation
- 1996-04-17 AR ARP960102210A patent/AR004663A1/es unknown
- 1996-04-17 AP APAP/P/1996/000827A patent/AP9600827A0/en unknown
- 1996-04-18 AU AU56655/96A patent/AU712913B2/en not_active Expired
- 1996-04-18 WO PCT/US1996/005473 patent/WO1996033187A1/en not_active Ceased
- 1996-04-18 DE DE69635679T patent/DE69635679T2/de not_active Expired - Lifetime
- 1996-04-18 EE EE9700254A patent/EE9700254A/xx unknown
- 1996-04-18 AT AT01113575T patent/ATE314360T1/de active
- 1996-04-18 SK SK1430-97A patent/SK143097A3/sk unknown
- 1996-04-18 CA CA2217745A patent/CA2217745C/en not_active Expired - Lifetime
- 1996-04-18 PT PT96913811T patent/PT833826E/pt unknown
- 1996-04-18 IL IL11796296A patent/IL117962A0/xx unknown
- 1996-04-18 ES ES01113575T patent/ES2256117T3/es not_active Expired - Lifetime
- 1996-04-18 EP EP05028389A patent/EP1637528B1/en not_active Expired - Lifetime
- 1996-04-18 KR KR1019970707346A patent/KR100485237B1/ko not_active Expired - Lifetime
- 1996-04-18 PE PE1996000266A patent/PE43697A1/es not_active Application Discontinuation
- 1996-04-18 CZ CZ973294A patent/CZ329497A3/cs unknown
- 1996-04-18 EA EA199700330A patent/EA000906B1/ru not_active IP Right Cessation
- 1996-04-18 EP EP01113575A patent/EP1136479B1/en not_active Expired - Lifetime
- 1996-04-18 AP APAP/P/1997/001104A patent/AP862A/en active
- 1996-04-18 DK DK96913811T patent/DK0833826T3/da active
- 1996-04-18 DE DE69638252T patent/DE69638252D1/de not_active Expired - Lifetime
- 1996-04-18 CN CN96193903A patent/CN1110491C/zh not_active Expired - Fee Related
- 1996-04-18 JP JP53195396A patent/JP4240532B2/ja not_active Expired - Lifetime
- 1996-04-18 TR TR97/01194T patent/TR199701194T1/xx unknown
- 1996-04-18 ES ES05028389T patent/ES2351970T3/es not_active Expired - Lifetime
- 1996-04-18 ES ES96913811T patent/ES2171670T3/es not_active Expired - Lifetime
- 1996-04-18 AT AT96913811T patent/ATE212344T1/de active
- 1996-04-18 DE DE69618779T patent/DE69618779T2/de not_active Expired - Lifetime
- 1996-04-18 EP EP96913811A patent/EP0833826B1/en not_active Expired - Lifetime
- 1996-04-18 MY MYPI96001465A patent/MY115797A/en unknown
- 1996-04-18 AT AT05028389T patent/ATE479674T1/de not_active IP Right Cessation
- 1996-04-18 HU HU9801948A patent/HUP9801948A3/hu unknown
- 1996-04-18 GE GEAP19963972A patent/GEP20001915B/en unknown
- 1996-04-18 BR BR9608033A patent/BR9608033A/pt not_active Application Discontinuation
- 1996-04-18 PL PL96322904A patent/PL322904A1/xx unknown
- 1996-04-19 CO CO96019067A patent/CO4700433A1/es unknown
1997
- 1997-10-02 IS IS4575A patent/IS4575A/is unknown
- 1997-10-08 NZ NZ307342A patent/NZ307342A/en unknown
- 1997-10-14 NO NO974744A patent/NO974744D0/no not_active Application Discontinuation
- 1997-11-13 BG BG102041A patent/BG102041A/xx unknown
- 1997-11-24 US US08/977,365 patent/US5990155A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5990155A (en)	1999-11-23
DE69618779D1 (de)	2002-03-14
AU5665596A (en)	1996-11-07
MY115797A (en)	2003-09-30
TR199701194T1 (xx)	1998-03-21
EP0833826B1 (en)	2002-01-23
IS4575A (is)	1997-10-02
US5691372A (en)	1997-11-25
HUP9801948A3 (en)	2002-04-29
JPH11504628A (ja)	1999-04-27
DE69618779T2 (de)	2002-08-29
EP0833826A1 (en)	1998-04-08
ES2351970T3 (es)	2011-02-14
AP9600827A0 (en)	1997-10-17
EP1136479B1 (en)	2005-12-28
PT833826E (pt)	2002-06-28
DE69635679D1 (de)	2006-02-02
EE9700254A (et)	1998-04-15
ES2256117T3 (es)	2006-07-16
WO1996033187A1 (en)	1996-10-24
ATE212344T1 (de)	2002-02-15
DE69635679T2 (de)	2006-08-31
ATE479674T1 (de)	2010-09-15
PE43697A1 (es)	1997-10-11
ATE314360T1 (de)	2006-01-15
TW404945B (en)	2000-09-11
ZA962891B (en)	1996-10-15
EP1136479A1 (en)	2001-09-26
JP4240532B2 (ja)	2009-03-18
AU712913B2 (en)	1999-11-18
ES2171670T3 (es)	2002-09-16
HK1009811A1 (en)	1999-06-11
CO4700433A1 (es)	1998-12-29
KR100485237B1 (ko)	2005-09-30
EA199700330A1 (ru)	1998-04-30
SK143097A3 (en)	1998-03-04
DE69638252D1 (de)	2010-10-14
BG102041A (en)	1998-09-30
HUP9801948A2 (hu)	1999-09-28
HK1092791A1 (en)	2007-02-16
NZ307342A (en)	1999-04-29
IL117962A0 (en)	1996-08-04
EP1637528A1 (en)	2006-03-22
EP1637528B1 (en)	2010-09-01
CN1110491C (zh)	2003-06-04
EA000906B1 (ru)	2000-06-26
DK0833826T3 (da)	2002-05-06
CZ329497A3 (cs)	1998-03-18
AP9701104A0 (en)	1997-10-31
CA2217745C (en)	2011-07-05
PL322904A1 (en)	1998-03-02
GEP20001915B (en)	2000-01-05
CA2217745A1 (en)	1996-10-24
NO974744L (no)	1997-10-14
AP862A (en)	2000-08-04
NO974744D0 (no)	1997-10-14
AR004663A1 (es)	1999-03-10
CN1184474A (zh)	1998-06-10
KR19990007823A (ko)	1999-01-25

Publication	Publication Date	Title
BR9608033A (pt)	1999-01-12	Inibidores de aspartil protease de heterociclo oxigenado contendo sulfonamida
EE9700266A (et)	1998-04-15	Aspartüüli proteaasi THF-i sisaldavad sulfoonamiidinhibiitorid
NO20006717D0 (no)	2000-12-29	Proteaseinhibitorer
EE200000386A (et)	2001-12-17	Aspartüülproteaasi inhibiitorite eelravimid
PT936912E (pt)	2004-06-30	Inibidores de cisteina protease
NO974403D0 (no)	1997-09-23	Reversible proteasehemmere
FI942423A7 (fi)	1994-11-26	Sakkariinijohdannisia proteolyyttisen entsyymin inhibiittoreina
NO932620D0 (no)	1993-07-20	Amindiol-proteaseinhibitorer
EE200000385A (et)	2001-12-17	Sulfoonamiidi derivaadid kui aspartüülproteaasi inhibiitorid
NO975742D0 (no)	1997-12-05	Reversible cysteinproteasehemmere
NO20006405D0 (no)	2000-12-15	Sulfonamidinhibitorer for aspartylprotease
NO995433D0 (no)	1999-11-05	Protease-inhibitorer
NO992734D0 (no)	1999-06-04	Serin-protease inhibitorer
ATE325091T1 (de)	2006-06-15	Aspartyl-protease inhibitoren
NO983688D0 (no)	1998-08-12	Serin-protease-inhibitorer
NO995268D0 (no)	1999-10-28	Proteaseinhibitorer
NO995434L (no)	1999-11-05	Proteaseinhibitorer
DE69730871D1 (de)	2004-10-28	Serine-protease-inhibitoren
ATE221080T1 (de)	2002-08-15	Serine-protease-inhibitoren
AP9700961A0 (en)	1997-04-30	Aspartyl protease inhibitors
ZA97613B (en)	1997-07-30	Aspartyl protease inhibitors
NO980643D0 (no)	1998-02-16	Propylendopeptidase inhibitorer
MX9206568A (es)	1993-05-01	Derivados de sacarina inhibidores de enzimas proteoliticas.
BR9612344A (pt)	1999-07-13	Inibidores de proteases
MA26429A1 (fr)	2004-12-20	Inhibiteurs de protease

Legal Events

Date	Code	Title	Description
2004-12-07	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2005-06-07	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements